Amended Statement of Ownership (sc 13g/a)
July 15 2020 - 10:56AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. 1)*
Innovation
Pharmaceuticals Inc.
(Name
of Issuer)
|
|
Common
Stock Class A, $0.0001 par value
(Title
of Class of Securities)
|
|
15115V101
(CUSIP
Number)
|
|
July
13, 2020
(Date
of Event Which Requires Filing of this Statement)
|
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
* The
remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior
cover page.
The
information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act.
CUSIP NO. 15115V101
|
13G
|
Page
2 of 4 Pages
|
1
|
|
NAME
OF REPORTING PERSON:
Leviston Resources LLC
|
|
|
|
2
|
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
|
(a) ☐
|
|
|
|
|
(b) ☐
|
|
|
|
|
|
|
3
|
|
SEC
USE ONLY
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
|
|
|
Delaware
|
|
|
|
|
|
5
|
|
SOLE
VOTING POWER
|
NUMBER
OF
|
|
|
|
15,960,000
shares of Common Stock Class A
|
SHARES
|
|
|
BENEFICIALLY
|
|
6
|
|
SHARED
VOTING POWER
|
OWNED
|
|
|
|
None
|
BY
|
|
|
EACH
|
|
7
|
|
SOLE
DISPOSITIVE POWER
|
REPORTING
|
|
|
|
15,960,000
shares of Common Stock Class A
|
PERSON
|
|
|
WITH:
|
|
8
|
|
SHARED
DISPOSITIVE POWER
|
|
|
|
|
None
|
9
|
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
15,960,000
shares of Common Stock Class A
|
|
|
|
10
|
|
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
|
|
☐
|
|
|
|
|
|
|
11
|
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
4.9%
|
|
|
|
12
|
|
TYPE
OF REPORTING PERSON*
|
|
|
|
|
OO
|
|
|
CUSIP NO. 15115V101
|
13G
|
Page
3 of 4 Pages
|
ITEM
1(a).
|
NAME
OF ISSUER:
|
Innovation
Pharmaceuticals Inc.
ITEM
1(b).
|
ADDRESS
OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
|
301
Edgewater Place, Suite 100
Wakefield,
MA
ITEM
2(a).
|
NAME
OF PERSON FILING:
|
This
Schedule 13G is being filed on behalf of the following:
|
(i)
|
Leviston
Resources LLC
|
ITEM
2(b).
|
ADDRESS
OF PRINCIPAL BUSINESS OFFICE:
|
Address
of principal business or, if none, residence:
|
(i)
|
155
E 44th St, New York, NY 10017
|
|
(i)
|
Leviston
Resources LLC is a Delaware limited liability company
|
ITEM
2(d).
|
TITLE
OF CLASS OF SECURITIES:
|
Common
Stock Class A, $0.0001 par value
15115V101
ITEM
3.
|
IF
THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
|
(a)
☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
(e)
☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company
Act of 1940 (15 U.S.C. 80a-3);
(j)
☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k)
☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §
240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____
CUSIP NO. 15115V101
|
13G
|
Page
4 of 4 Pages
|
(a)
|
Amount
beneficially owned:
|
15,960,000
shares of Common Stock Class A
|
(b)
|
Percent
of class:
|
4.9%
|
(c)
|
Number
of shares as to which the person has:
|
|
|
(i)
|
Sole
power to vote or to direct the vote:
|
15,960,000
shares of Common Stock Class A
|
|
(ii)
|
Shared
power to vote or to direct the vote:
|
None
|
|
(iii)
|
Sole
power to dispose or to direct the disposition of:
|
15,960,000
shares of Common Stock Class A
|
|
(iv)
|
Shared
power to dispose or to direct the disposition of:
|
None
|
|
ITEM
5.
|
OWNERSHIP
OF FIVE PERCENT OR LESS OF A CLASS:
|
If
this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial
owner of more than five percent of the class of securities check the following. ☒*
*
This Amendment No. 1 constitutes an exit filing for Leviston Resources LLC, which as of July 13, 2020, no longer beneficially
owned more than 5% of the outstanding securities of Innovation Pharmaceuticals Inc.
|
ITEM
6.
|
OWNERSHIP
OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
|
Not
applicable.
|
ITEM
7.
|
IDENTIFICATION
AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
|
Not
applicable.
|
ITEM
8.
|
IDENTIFICATION
AND CLASSIFICATION OF MEMBERS OF A GROUP:
|
Not
applicable.
|
ITEM
9.
|
NOTICE
OF DISSOLUTION OF GROUP:
|
Not
applicable.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under §240.14a-11.
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
LEVISTON
RESOURCES LLC
|
|
|
|
|
By:
|
/s/
J. Miller
|
|
Name:
|
J.
Miller
|
|
Date:
|
July
14, 2020
|
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Mar 2023 to Mar 2024